Staar Surgical Co: Form 10-Q for the period ended Jun 27, 2025
Filed with the SEC on Aug 6, 2025 and accepted by EDGAR at Aug 6, 2025, 16:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-27. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-03-29 to 2025-06-27 | $44.3m | us-gaap:Revenues |
| Revenue | 6 months2024-12-28 to 2025-06-27 | $86.9m | us-gaap:Revenues |
| Cost of revenue | 3 months2025-03-29 to 2025-06-27 | $11.5m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2024-12-28 to 2025-06-27 | $26.1m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2025-03-29 to 2025-06-27 | $32.8m | us-gaap:GrossProfit |
| Gross profit | 6 months2024-12-28 to 2025-06-27 | $60.8m | us-gaap:GrossProfit |
| Research and development | 3 months2025-03-29 to 2025-06-27 | $10.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-12-28 to 2025-06-27 | $21.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2025-03-29 to 2025-06-27 | $62.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2024-12-28 to 2025-06-27 | $148.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-03-29 to 2025-06-27 | −$30.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-12-28 to 2025-06-27 | −$87.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-03-29 to 2025-06-27 | −$9.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-12-28 to 2025-06-27 | −$9.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-03-29 to 2025-06-27 | −$16.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-12-28 to 2025-06-27 | −$71.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-03-29 to 2025-06-27 | −$0.34 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-12-28 to 2025-06-27 | −$1.44 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-03-29 to 2025-06-27 | −$0.34 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-12-28 to 2025-06-27 | −$1.44 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-03-29 to 2025-06-27 | 49,520,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-12-28 to 2025-06-27 | 49,432,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-12-28 to 2025-06-27 | −$33.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-12-28 to 2025-06-27 | $3.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2024-12-28 to 2025-06-27 | $4.5m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2025-06-27 | $167.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-27 | $292.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-27 | $437.8m | us-gaap:Assets |
| Current liabilities | At period end2025-06-27 | $59.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-27 | $101.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-06-27 | $336.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-25-103982. Last ingested by Listed: Nov 4, 2026, 17:00 ET. Listed shows no prices and gives no investment advice.